SF1126 is a water soluble, small-molecule prodrug containing the pan-PI3K/mTOR inhibitor LY294002/SF1101 conjugated to the RGD-containing tetra-peptide SF1174 with potential antineoplastic and antiangiogenic activities.
More Information Supplier PageSCH900776 is an agent targeting cell cycle checkpoint kinase 1 (Chk1) with potential radiosensitization and chemosensitization activities.
More Information Supplier PageSCH900776 is an agent targeting cell cycle checkpoint kinase 1 (Chk1) with potential radiosensitization and chemosensitization activities.
More Information Supplier PageSCH900776 is an agent targeting cell cycle checkpoint kinase 1 (Chk1) with potential radiosensitization and chemosensitization activities.
More Information Supplier PageSCH900776 is an agent targeting cell cycle checkpoint kinase 1 (Chk1) with potential radiosensitization and chemosensitization activities.
More Information Supplier PageFR901464 is a potent anticancer natural product that lowers the mRNA levels of oncogenes and tumor suppressor genes.
More Information Supplier PageFR901464 is a potent anticancer natural product that lowers the mRNA levels of oncogenes and tumor suppressor genes.
More Information Supplier PageFR901464 is a potent anticancer natural product that lowers the mRNA levels of oncogenes and tumor suppressor genes.
More Information Supplier PageFR901464 is a potent anticancer natural product that lowers the mRNA levels of oncogenes and tumor suppressor genes.
More Information Supplier PagePacritinib, also known as SB1518, is an orally bioavailable inhibitor of Janus kinase 2 (JAK2) and the JAK2 mutant JAK2V617F with potential antineoplastic activity. Pacritinib competes with JAK2 for ATP binding, which may result in inhibition of JAK2 activation, inhibition of the JAK-STAT signaling pathway, and so caspase-dependent apoptosis.
More Information Supplier Page
